Sarah K Tasian, MD

faculty photo
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Division of Oncology
Hematologic Malignancies section
3501 Civic Center Boulevard, CTRB 3010
Philadelphia, PA 19104
Office: 215.590.5476 (admin)
Education:
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
(Pediatrics Residency)
Seattle Children's Hospital and University of Washington, 2007.
(Pediatric Hematology-Oncology Fellowship)
University of California, San Francisco (UCSF), 2011.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of comprehensive leukemia genetic data with therapy selection for children with high risk newly-diagnosed and relapsed ALL and AML with a focus on precision medicine treatment approaches.

I attend on the Hematologic Malignancies inpatient service and outpatient Oncology clinic at the Children's Hospital of Philadelphia. I have procedural expertise in lumbar punctures, Ommaya reservoir taps, administration of intrathecal chemotherapy, and bone marrow aspiration and biopsy.

Description of Other Expertise

I am a primary clinical mentor in Hematologic Malignancies for first, second, and third year pediatric hematology-oncology fellows and supervise their patient care in the inpatient and outpatient clinical settings. I also teach and supervise pediatric residents in the inpatient setting.

Description of Research Expertise

My career goal as an academic physician-scientist is to develop molecularly-targeted therapies for children with high-risk leukemias to prevent relapse, improve survival, and minimize toxicities.

My independent translational research program focuses upon novel therapeutics for high-risk pediatric leukemias via:
(1) Characterization of signal transduction networks and preclinical testing of kinase inhibitors for subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
(2) Preclinical testing of leukemia antigen-redirected chimeric antigen receptor (CAR) T cell immunotherapy for childhood AML
(3) Early phase clinical trial testing of targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia

Successful integration of our bench-based and clinical studies has led to several trials testing new therapies in children with high-risk leukemias. I have leadership roles in the COG ALL, Myeloid Diseases, and AML New Agents steering committees and am the COG Developmental Therapeutics Committee Vice Chair of Biology for Hematologic Malignancies. I also chair the COG phase 2 clinical trial AALL1521 (ruxolitinib/chemotherapy for children with CRLF2/JAK pathway-mutant Ph-like ALL), co-lead development of immunotherapy trials for children with relapsed AML, and am PI of the CHOP Center for Childhood for Cancer Research leukemia biorepository.

Selected Publications

Tasian SK: Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol 9(6): in press, June 2018.

Loftus JP, Yahioui A, Shen F, Hurtz C, Brown PA, Tannheimer S, Forslund A, Tasian SK: Enhanced Efficacy of the SYK Inhibitor Entospletinib and Vincristine in KMT2A-Rearranged Acute Lymphoblastic Leukemia. European Hematology Association Page: abstract PF164, June 2018 Notes: Poster presentation at Annual Meeting; Stockholm, Sweden.

Ding Yang Y, Stern Julie W, Jubelirer Tracey F, Wertheim Gerald B, Li Fumin, Chang Fengqi, Gu Zhaohui, Mullighan Charles G, Li Yong, Harvey Richard C, Chen I-Ming, Willman Cheryl L, Hunger Stephen P, Li Marilyn M, Tasian Sarah K: Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica May 2018.

Loftus JP, Yahioui A, Shen F, Hurtz C, Brown PA, Tannheimer S, Forslund A, Tasian SK: Efficacy of the SYK Inhibitor Entospletinib and Vincristine in Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia Xenograft Models. International BFM Childhood Leukemia and Lymphoma Symposium Page: abstract O18, May 2018 Notes: Oral presentation at 11th Biennial Meeting; Helsinki, Finland.

Chien CD, Yang Y, Sauter CT, Ishii K, Nguyen SM, Shen F, Tasian SK, Fry TJ: FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia. American Association for Cancer Research April 2018 Notes: Oral presentation at annual meeting; Chicago, IL.

Akgumus G, Zelley K, Gallo DJ, Surrey LF, Aplenc R, Bagatell R, Bhatti T, Hunger SP, Luo M, Maris JM, Mosse Y, Santi M, Tasian SK, Waanders A, Brodeur GM, Li MM: A Practical Algorithm for Evaluation of Potential Germline Variants from Tumor-Only Sequencing. American College of Medical Genetics and Genomics April 2018 Notes: Oral presentation at Clinical Genetics annual meeting; Charlotte, NC.

Hurtz C, Wertheim GB, Ruggeri B, Stubbs MC, Perl AE, Carroll M, Tasian SK: Essential JAK, PI3K, and SRC Signaling Pathways Regulate Cell Survival in Philadelphia Chromosome-Like ALL. American Society of Clinical Investigation Annual Meeting April 2018 Notes: Poster presentation at ASCI Young Investigator Induction and Food and Science Evening; Chicago, IL.

Tasian SK, Bornhäuser M, Rutella S: Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines 6(1): 22, Feb 2018.

Tasian SK: Researcher Spotlight. Conquer Cancer Foundation/ASCO February 2018 Notes: https://connection.asco.org/magazine/features/optimistic-end-campaign-conquer-cancer.

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M.: Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget 9(8): 8027-8041, Jan 2018.

back to top
Last updated: 07/13/2018
The Trustees of the University of Pennsylvania